Arm A (short course RT) for Glioblastoma

Mayo Clinic in Rochester, Rochester, MN
GlioblastomaAccelerated Hypofractionated Radiation Therapy - Radiation
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will compare a shorter course of radiation therapy to the standard of care for brain cancer patients. It hopes to find a more effective treatment with fewer side effects.

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: From baseline up to 3 years

Year 3
Lymphocyte count
Quality of life
Month 12
Proportion of patients alive (overall survival [OS]) at 12 months
Up to 30-, 90-, and 180-days post-radiotherapy (RT)
Proportion of patients whose physician reported a grade 3+ toxicity

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

2 Treatment Groups

Arm B (standard course RT)
1 of 2
Arm A (short course RT)
1 of 2

Active Control

Experimental Treatment

170 Total Participants · 2 Treatment Groups

Primary Treatment: Arm A (short course RT) · No Placebo Group · Phase 2

Arm A (short course RT)Experimental Group · 8 Interventions: Accelerated Hypofractionated Radiation Therapy, Fluorodopa F 18, Computed Tomography, Positron Emission Tomography, Questionnaire Administration, Magnetic Resonance Imaging, Temozolomide, Quality-of-Life Assessment · Intervention Types: Radiation, Drug, Procedure, Procedure, Other, Procedure, Drug, Other
Arm B (standard course RT)ActiveComparator Group · 8 Interventions: Fluorodopa F 18, Computed Tomography, Positron Emission Tomography, Questionnaire Administration, Magnetic Resonance Imaging, Temozolomide, Quality-of-Life Assessment, Radiation Therapy · Intervention Types: Drug, Procedure, Procedure, Other, Procedure, Drug, Other, Radiation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Computed Tomography
2017
Completed Phase 2
~2710
Positron Emission Tomography
2008
Completed Phase 2
~2290
Magnetic Resonance Imaging
2017
Completed Phase 3
~1180
Temozolomide
2010
Completed Phase 3
~1940

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: from baseline up to 3 years

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,005 Previous Clinical Trials
3,512,510 Total Patients Enrolled
12 Trials studying Glioblastoma
362 Patients Enrolled for Glioblastoma
William G BreenPrincipal InvestigatorMayo Clinic in Rochester
1 Previous Clinical Trials
20 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Is this trial currently recruiting participants?

"Per information held on clinicaltrials.gov, the aforementioned medical trial is no longer searching for patients. Initially posted in March 27th 2023, with its last update dated March 19th 23rd; however 458 other studies are still recruiting participants as of now." - Anonymous Online Contributor

Unverified Answer

Does the Food and Drug Administration recognize Arm A (short course RT) as being an acceptable therapeutic approach?

"Our team at Power has ascribed a score of 2 to Arm A (short course RT) on the basis that this is Phase 2 trial, which implies there are some data suggesting safety but no evidence supporting efficacy." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.